Analysts rate Global Blood Therapeutics Inc. stock with a consensus Strong Buy rating and a 12-month average target price of $62.67 per share.
Cantor Fitzgerald initiated Global Blood Therapeutics Inc. with a Buy rating and sets the target price at $75 on the company’s stock.
Based on the Global Blood Therapeutics Inc stock forecasts from 8 analysts, the average analyst target price for Global Blood Therapeutics Inc is USD 62.67 over the next 12 months. Global Blood Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Global Blood Therapeutics Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Global Blood Therapeutics Inc’s stock price was USD 32.34. Global Blood Therapeutics Inc’s stock price has changed by -9.31% over the past week, -6.10% over the past month and -21.81% over the last year.
What we like:
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What we don’t like:
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The company had negative total cash flow in the most recent four quarters.
Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.